Trend of A-share and Hong Kong stock innovative medicine sector this week
In the second week of January 2022, a total of 37 stocks in the innovative drug sector in mainland and Hong Kong rose and 10 stocks fell. Among them, Shanghai Junshi Biosciences Co.Ltd(688180) – U (+ 33.72%), Frontier Biotechnologies Inc(688221) – U (+ 31.49%) and Shanghai Junshi Biosciences Co.Ltd(688180) (+ 23.53%). The top three declines were heyu-b (- 9.50%), tengshengbo medicine-b (- 25.34%) and Yongtai biology-b (- 51.19%). This week, the A-share innovative drug sector fell 7.09%, underperforming the CSI 300 index by 1.98pp, and biomedicine rose 3.06%. In the past six months, A-share innovative drugs fell by 15.82%, underperforming the CSI 300 index by 7.06pp, and biomedicine fell by 30.30%. This week, the innovative drug sector of Hong Kong stocks rose 5.15%, outperforming the Hang Seng Index by 3.79pp, and Hang Seng healthcare fell 7.07%. Over the past six months, innovative drugs in Hong Kong stocks have fallen by 15.59%, underperforming the Hang Seng Index by 13.30pp, and Hang Seng health care has fallen by 44.68%.
Progress of key innovative drugs in China
In January, 8 new drugs were approved for marketing in China. This week, three new drugs were approved for listing, namely Betta Pharmaceuticals Co.Ltd(300558) voronib, Japan Xiehe Kirin romistine and shengnuoji icariin.
Progress of overseas key innovative drugs
This week, one NDA was approved by FDA, eight ind applications were approved by FDA, and one drug was approved by FDA for emergency use.
Weekly special topic – research and development progress of Pd / L1 + CTLA4 dual target drugs
BCMA targets are mainly targeted at multiple myeloma. A total of 114 projects are under research around the world, including 75 bcma-cart projects. Chinese enterprises are the most active in this field, accounting for 48 projects. The world’s first listed bcma-cart therapy was introduced by celgene from bluebirdbio. Listed in the United States on March 26, 2021. The progress of legendary biological sidakiolanza ranks second in the world. At present, it is in the NDA stage. The global promotion of the drug cooperates with Johnson & Johnson. Among Chinese companies, there are a total of 10 projects in the clinical stage. Listed companies also arrange bcma-cart, including Cinda biology, Keji pharmaceutical, Xiansheng pharmaceutical, Yaoming Juno, etc.
Progress of global key innovative drug transactions this week
There were 30 key transactions in the world this week, and 20 key transactions with disclosed amount. 1) Everest medicines has signed a global license agreement to develop and commercialize the 3CL protease inhibitor of Singapore experimental drug development center as a potential global best-in-class covid-19 oral antiviral drug. 2) Salarius pharmaceuticals expands its tumor product line by strategically acquiring a targeted protein degradation product portfolio from deuterx, LLC. 3) Scorpion therapeutics has reached an agreement with AstraZeneca to discover, develop and commercialize new cancer treatments for “non drug” targets. 4) Journey Medical Corporation acquired two FDA approved topical minocycline products and molecular stabilization technology (MST) from vyne therapeutics, Inc ™ Franchise rights.
Risk warning: expected risk of drug price reduction; The implementation progress of medical reform policy is lower than the expected risk; Risk of R & D failure.
